COVID-19 and emerging viral infections: The case for interferon lambda

Ludmila Prokunina-Olsson; Noémie Alphonse; Ruth E. Dickenson; Joan E. Durbin; Jeffrey S. Glenn; Rune Hartmann; Sergei V. Kotenko; Helen M. Lazear; Thomas R. O’Brien; Charlotte Odendall; Olusegun O. Onabajo; Helen Piontkivska; Deanna M. Santer; Nancy C. Reich; Andreas Wack; Ivan Zanoni

doi:10.1084/jem.20200653

COVID-19 and emerging viral infections: The case for interferon lambda

Ludmila Prokunina-Olsson
, Noémie Alphonse
, Ruth E. Dickenson
, Joan E. Durbin
, Jeffrey S. Glenn
, Rune Hartmann
, Sergei V. Kotenko
, Helen M. Lazear
, Thomas R. O’Brien
, Charlotte Odendall
, Olusegun O. Onabajo
, Helen Piontkivska
, Deanna M. Santer
, Nancy C. Reich
, Andreas Wack
, Ivan Zanoni

National Institutes of Health
King's College London
The Francis Crick Institute
Rutgers - The State University of New Jersey, New Brunswick
Stanford University
Aarhus University
University of North Carolina at Chapel Hill
Kent State University
University of Alberta
Boston Children's Hospital

Research output: Contribution to journal › Review article › peer-review

168 Scopus citations

Abstract

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

Original language	English
Article number	e20200653
Journal	Journal of Experimental Medicine
Volume	217
Issue number	5
DOIs	https://doi.org/10.1084/jem.20200653
State	Published - May 4 2020

Access to Document

10.1084/jem.20200653

Cite this

Prokunina-Olsson, L., Alphonse, N., Dickenson, R. E., Durbin, J. E., Glenn, J. S., Hartmann, R., Kotenko, S. V., Lazear, H. M., O’Brien, T. R., Odendall, C., Onabajo, O. O., Piontkivska, H., Santer, D. M., Reich, N. C., Wack, A., & Zanoni, I. (2020). COVID-19 and emerging viral infections: The case for interferon lambda. Journal of Experimental Medicine, 217(5), Article e20200653. https://doi.org/10.1084/jem.20200653

@article{0bc230be83264c3cb50f77921868751e,

title = "COVID-19 and emerging viral infections: The case for interferon lambda",

abstract = "With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.",

author = "Ludmila Prokunina-Olsson and No{\'e}mie Alphonse and Dickenson, \{Ruth E.\} and Durbin, \{Joan E.\} and Glenn, \{Jeffrey S.\} and Rune Hartmann and Kotenko, \{Sergei V.\} and Lazear, \{Helen M.\} and O{\textquoteright}Brien, \{Thomas R.\} and Charlotte Odendall and Onabajo, \{Olusegun O.\} and Helen Piontkivska and Santer, \{Deanna M.\} and Reich, \{Nancy C.\} and Andreas Wack and Ivan Zanoni",

note = "Publisher Copyright: {\textcopyright} 2020 Prokunina-Olsson et al.",

year = "2020",

month = may,

day = "4",

doi = "10.1084/jem.20200653",

language = "English",

volume = "217",

journal = "Journal of Experimental Medicine",

issn = "0022-1007",

number = "5",

}

Prokunina-Olsson, L, Alphonse, N, Dickenson, RE, Durbin, JE, Glenn, JS, Hartmann, R, Kotenko, SV, Lazear, HM, O’Brien, TR, Odendall, C, Onabajo, OO, Piontkivska, H, Santer, DM, Reich, NC, Wack, A & Zanoni, I 2020, 'COVID-19 and emerging viral infections: The case for interferon lambda', Journal of Experimental Medicine, vol. 217, no. 5, e20200653. https://doi.org/10.1084/jem.20200653

TY - JOUR

T1 - COVID-19 and emerging viral infections

T2 - The case for interferon lambda

AU - Prokunina-Olsson, Ludmila

AU - Alphonse, Noémie

AU - Dickenson, Ruth E.

AU - Durbin, Joan E.

AU - Glenn, Jeffrey S.

AU - Hartmann, Rune

AU - Kotenko, Sergei V.

AU - Lazear, Helen M.

AU - O’Brien, Thomas R.

AU - Odendall, Charlotte

AU - Onabajo, Olusegun O.

AU - Piontkivska, Helen

AU - Santer, Deanna M.

AU - Reich, Nancy C.

AU - Wack, Andreas

AU - Zanoni, Ivan

PY - 2020/5/4

Y1 - 2020/5/4

N2 - With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

AB - With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

UR - https://www.scopus.com/pages/publications/85084343152

U2 - 10.1084/jem.20200653

DO - 10.1084/jem.20200653

M3 - Review article

AN - SCOPUS:85084343152

SN - 0022-1007

VL - 217

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

IS - 5

M1 - e20200653

ER -

COVID-19 and emerging viral infections: The case for interferon lambda

Abstract

Access to Document

Other files and links

Fingerprint

Cite this